Allianz Asset Management GmbH purchased a new position in Neuroderm Ltd (NASDAQ:NDRM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 541,544 shares of the biotechnology company’s stock, valued at approximately $21,066,000. Allianz Asset Management GmbH owned approximately 2.06% of Neuroderm as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of NDRM. Opera Trading Capital acquired a new stake in Neuroderm in the third quarter worth about $140,000. Van ECK Associates Corp boosted its holdings in Neuroderm by 11.0% in the second quarter. Van ECK Associates Corp now owns 4,723 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 468 shares in the last quarter. Vanguard Group Inc. acquired a new stake in Neuroderm in the second quarter worth about $210,000. ETF Managers Group LLC acquired a new stake in Neuroderm in the second quarter worth about $210,000. Finally, Oppenheimer & Co. Inc. boosted its holdings in Neuroderm by 0.4% in the second quarter. Oppenheimer & Co. Inc. now owns 8,442 shares of the biotechnology company’s stock worth $252,000 after acquiring an additional 30 shares in the last quarter. 52.39% of the stock is owned by institutional investors and hedge funds.

Shares of Neuroderm Ltd (NDRM) opened at $38.85 on Tuesday. Neuroderm Ltd has a twelve month low of $15.20 and a twelve month high of $38.95.

Several brokerages have weighed in on NDRM. Zacks Investment Research raised Neuroderm from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Jefferies Group reissued a “buy” rating and issued a $42.00 price target on shares of Neuroderm in a report on Monday, August 14th. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Neuroderm has a consensus rating of “Buy” and an average price target of $45.86.

WARNING: “Allianz Asset Management GmbH Invests $21.07 Million in Neuroderm Ltd (NDRM) Stock” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/allianz-asset-management-gmbh-invests-21-07-million-in-neuroderm-ltd-ndrm-stock/1758821.html.

Neuroderm Profile

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.

Institutional Ownership by Quarter for Neuroderm (NASDAQ:NDRM)

Receive News & Ratings for Neuroderm Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuroderm Ltd and related companies with MarketBeat.com's FREE daily email newsletter.